{"Drugs":{"Drug":{"Id":47000,"DrugType":{"Type":"Small molecule therapeutic"},"DrugTargetMaturity":{"TargetIndication":[{"IndicationId":1744,"IndicationName":"Mantle cell lymphoma","MinPatentApplicationDate":"2006-07-25T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":316,"IndicationName":"B-cell lymphoma","MinPatentApplicationDate":"2006-07-25T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":1735,"IndicationName":"Chronic myelocytic leukemia","MinPatentApplicationDate":"2006-07-25T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":1272,"IndicationName":"Myelodysplastic syndrome","MinPatentApplicationDate":"2006-07-25T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":203,"IndicationName":"Lymphoma","MinPatentApplicationDate":"2010-02-24T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":161,"IndicationName":"Hodgkins disease","MinPatentApplicationDate":"2006-01-12T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":1728,"IndicationName":"Acute lymphoblastic leukemia","MinPatentApplicationDate":"2006-07-25T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":1734,"IndicationName":"Chronic lymphocytic leukemia","MinPatentApplicationDate":"2006-01-12T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":1749,"IndicationName":"Diffuse large B-cell lymphoma","MinPatentApplicationDate":"2009-06-19T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":1143,"IndicationName":"Amyloidosis","MinPatentApplicationDate":"2006-07-25T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":1731,"IndicationName":"Acute myelogenous leukemia","MinPatentApplicationDate":"2009-10-07T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":1745,"IndicationName":"Follicle center lymphoma","MinPatentApplicationDate":"2012-06-15T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":1828,"IndicationName":"Multiple myeloma","MinPatentApplicationDate":"2006-01-12T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":1748,"IndicationName":"Plasmacytoma","MinPatentApplicationDate":"2006-07-25T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":3866,"IndicationName":"Metastatic ovary cancer","MinPatentApplicationDate":"2013-12-04T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"},{"IndicationId":319,"IndicationName":"Non-Hodgkin lymphoma","MinPatentApplicationDate":"2006-01-12T00:00:00Z","TargetId":"PTGT-01514","TargetName":"PARP"}]},"DevelopmentStatusCurrent":{"Row":[{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"IE","$":"Ireland"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2014-11-30T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1716439"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"IE","$":"Ireland"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2014-11-30T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1716439"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"IE","$":"Ireland"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2014-11-30T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1716439"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"HK","$":"Hong Kong"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2011-07-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"1206349"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2008-04-30T00:00:00Z","SourceLink":{"@type":"PR","@id":"929302"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2019-05-26T00:00:00Z","SourceLink":{"@type":"PR","@id":"2157398"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"HK","$":"Hong Kong"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2011-07-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"1206349"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2011-06-03T00:00:00Z","SourceLink":{"@type":"PR","@id":"1200364"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2016-08-26T00:00:00Z","SourceLink":{"@type":"PR","@id":"1791311"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"SG","$":"Singapore"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2010-09-07T00:00:00Z","SourceLink":{"@type":"PR","@id":"1128644"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"KR","$":"South Korea"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2011-10-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"1259682"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1745","$":"Follicle center lymphoma"},"StatusDate":"2018-07-02T00:00:00Z","SourceLink":{"@type":"PR","@id":"2050798"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"203","$":"Lymphoma"},"StatusDate":"2019-03-26T00:00:00Z","SourceLink":{"@type":"PR","@id":"2134776"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2010-12-10T00:00:00Z","SourceLink":{"@type":"PR","@id":"1155487"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"KR","$":"South Korea"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2011-10-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"1259682"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2010-12-10T00:00:00Z","SourceLink":{"@type":"PR","@id":"1155487"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"SG","$":"Singapore"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2010-09-07T00:00:00Z","SourceLink":{"@type":"PR","@id":"1128644"}},{"Company":{"@id":"1047623","$":"Innopharmax Inc"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2012-02-24T00:00:00Z","SourceLink":{"@type":"PR","@id":"1266419"}},{"Company":{"@id":"1047623","$":"Innopharmax Inc"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2012-02-24T00:00:00Z","SourceLink":{"@type":"PR","@id":"1266419"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"AU","$":"Australia"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2018-01-09T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"2136487"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"NZ","$":"New Zealand"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2016-08-01T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"2168099"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"AU","$":"Australia"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2018-01-09T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"2136487"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"NZ","$":"New Zealand"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2016-08-01T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"2168099"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"AR","$":"Argentina"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1069","$":"Metastasis"},"StatusDate":"2018-02-06T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"2168096"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"AU","$":"Australia"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2018-01-09T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"2136487"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"NZ","$":"New Zealand"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2016-08-01T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"2168099"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2011-10-24T00:00:00Z","SourceLink":{"@type":"PR","@id":"1232992"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2007-04-01T00:00:00Z","SourceLink":{"@type":"PR","@id":"735208"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"IS","$":"Iceland"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2013-02-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1679139"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"NO","$":"Norway"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2013-02-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1679139"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"CH","$":"Switzerland"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2011-10-24T00:00:00Z","SourceLink":{"@type":"PR","@id":"1232992"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2011-10-24T00:00:00Z","SourceLink":{"@type":"PR","@id":"1232992"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2007-04-01T00:00:00Z","SourceLink":{"@type":"PR","@id":"735208"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"IS","$":"Iceland"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2013-02-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1679139"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"NO","$":"Norway"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2013-02-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1679139"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2011-10-24T00:00:00Z","SourceLink":{"@type":"PR","@id":"1232992"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2007-04-01T00:00:00Z","SourceLink":{"@type":"PR","@id":"735208"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"IS","$":"Iceland"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2013-02-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1679139"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"NO","$":"Norway"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2013-02-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1679139"}},{"Company":{"@id":"1118419","$":"Nuance Biotech Inc"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2019-05-26T00:00:00Z","SourceLink":{"@type":"PR","@id":"2157398"}},{"Company":{"@id":"20348","$":"Teva Pharmaceutical Industries Ltd"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2017-12-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"2003112"}},{"Company":{"@id":"20348","$":"Teva Pharmaceutical Industries Ltd"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2017-12-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"2003112"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"KR","$":"South Korea"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2014-06-16T00:00:00Z","SourceLink":{"@type":"PR","@id":"1570645"}},{"Company":{"@id":"1047623","$":"Innopharmax Inc"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2017-12-01T00:00:00Z","SourceLink":{"@type":"PR","@id":"1992824"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"BR","$":"Brazil"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2016-12-22T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"2057199"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2017-12-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"2003112"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"IL","$":"Israel"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1749","$":"Diffuse large B-cell lymphoma"},"StatusDate":"2017-08-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"1960295"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"KR","$":"South Korea"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"AR","$":"Argentina"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"BR","$":"Brazil"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"MX","$":"Mexico"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"PR","$":"Puerto Rico"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1745","$":"Follicle center lymphoma"},"StatusDate":"2017-12-12T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"2026712"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"X5","$":"Europe"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1749","$":"Diffuse large B-cell lymphoma"},"StatusDate":"2017-08-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"1960295"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"KR","$":"South Korea"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1143","$":"Amyloidosis"},"StatusDate":"2012-11-06T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1162545"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"IL","$":"Israel"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"316","$":"B-cell lymphoma"},"StatusDate":"2010-06-30T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1245209"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1749","$":"Diffuse large B-cell lymphoma"},"StatusDate":"2012-09-11T00:00:00Z"},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2009-05-31T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1094796"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"1728","$":"Acute lymphoblastic leukemia"},"StatusDate":"2012-03-27T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1017170"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"1731","$":"Acute myelogenous leukemia"},"StatusDate":"2012-03-27T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1017170"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"1735","$":"Chronic myelocytic leukemia"},"StatusDate":"2012-03-27T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1017170"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"1272","$":"Myelodysplastic syndrome"},"StatusDate":"2012-03-27T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1017170"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2014-02-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1531077"}},{"Company":{"@id":"17900","$":"H Lundbeck A/S"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2017-12-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"2003112"}},{"Company":{"@id":"17900","$":"H Lundbeck A/S"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2017-12-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"2003112"}},{"Company":{"@id":"17900","$":"H Lundbeck A/S"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2017-12-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"2003112"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2014-02-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1531077"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"NDR","@sortorder":"3","$":"No Development Reported"},"Indication":{"@id":"3866","$":"Metastatic ovary cancer"},"StatusDate":"2015-04-30T00:00:00Z"},{"Company":{"@id":"1047623","$":"Innopharmax Inc"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"NDR","@sortorder":"3","$":"No Development Reported"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2018-08-08T00:00:00Z"},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"NDR","@sortorder":"3","$":"No Development Reported"},"Indication":{"@id":"316","$":"B-cell lymphoma"},"StatusDate":"2014-08-31T00:00:00Z"},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"OL","@sortorder":"1","$":"Outlicensed"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2007-04-01T00:00:00Z","SourceLink":{"@type":"PR","@id":"735208"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"OL","@sortorder":"1","$":"Outlicensed"},"Indication":{"@id":"161","$":"Hodgkins disease"},"StatusDate":"2007-04-01T00:00:00Z","SourceLink":{"@type":"PR","@id":"735208"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"OL","@sortorder":"1","$":"Outlicensed"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2007-04-01T00:00:00Z","SourceLink":{"@type":"PR","@id":"735208"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"OL","@sortorder":"1","$":"Outlicensed"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2007-04-01T00:00:00Z","SourceLink":{"@type":"PR","@id":"735208"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"OL","@sortorder":"1","$":"Outlicensed"},"Indication":{"@id":"1748","$":"Plasmacytoma"},"StatusDate":"2007-04-01T00:00:00Z","SourceLink":{"@type":"PR","@id":"735208"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"OL","@sortorder":"1","$":"Outlicensed"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2011-02-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"1166676"}},{"Company":{"@id":"24030","$":"Jenapharm GmbH & Co KG"},"Country":{"@id":"DD","$":"East Germany (GDR)"},"DevelopmentStatus":{"@id":"OL","@sortorder":"1","$":"Outlicensed"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"1993-12-31T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}},{"Company":{"@id":"24030","$":"Jenapharm GmbH & Co KG"},"Country":{"@id":"DD","$":"East Germany (GDR)"},"DevelopmentStatus":{"@id":"OL","@sortorder":"1","$":"Outlicensed"},"Indication":{"@id":"161","$":"Hodgkins disease"},"StatusDate":"1993-12-31T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}},{"Company":{"@id":"24030","$":"Jenapharm GmbH & Co KG"},"Country":{"@id":"DD","$":"East Germany (GDR)"},"DevelopmentStatus":{"@id":"OL","@sortorder":"1","$":"Outlicensed"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"1993-12-31T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}},{"Company":{"@id":"24030","$":"Jenapharm GmbH & Co KG"},"Country":{"@id":"DD","$":"East Germany (GDR)"},"DevelopmentStatus":{"@id":"OL","@sortorder":"1","$":"Outlicensed"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"1993-12-31T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}},{"Company":{"@id":"24030","$":"Jenapharm GmbH & Co KG"},"Country":{"@id":"DD","$":"East Germany (GDR)"},"DevelopmentStatus":{"@id":"OL","@sortorder":"1","$":"Outlicensed"},"Indication":{"@id":"1748","$":"Plasmacytoma"},"StatusDate":"1993-12-31T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}}]},"DevelopmentStatusHistoric":{"Row":[{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"1996-02-06T00:00:00Z","SourceLink":{"@type":"PR","@id":"198292"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"161","$":"Hodgkins disease"},"StatusDate":"1996-02-06T00:00:00Z","SourceLink":{"@type":"PR","@id":"198292"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"1996-02-06T00:00:00Z","SourceLink":{"@type":"PR","@id":"198292"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"1996-02-06T00:00:00Z","SourceLink":{"@type":"PR","@id":"198292"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1748","$":"Plasmacytoma"},"StatusDate":"1996-02-06T00:00:00Z","SourceLink":{"@type":"PR","@id":"198292"}},{"Company":{"@id":"17900","$":"H Lundbeck A/S"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2012-09-13T00:00:00Z","SourceLink":{"@type":"PR","@id":"1323441"}},{"Company":{"@id":"17900","$":"H Lundbeck A/S"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2012-09-13T00:00:00Z","SourceLink":{"@type":"PR","@id":"1323441"}},{"Company":{"@id":"24030","$":"Jenapharm GmbH & Co KG"},"Country":{"@id":"DD","$":"East Germany (GDR)"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"1971-01-01T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}},{"Company":{"@id":"24030","$":"Jenapharm GmbH & Co KG"},"Country":{"@id":"DD","$":"East Germany (GDR)"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"161","$":"Hodgkins disease"},"StatusDate":"1971-01-01T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}},{"Company":{"@id":"24030","$":"Jenapharm GmbH & Co KG"},"Country":{"@id":"DD","$":"East Germany (GDR)"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"1971-01-01T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}},{"Company":{"@id":"24030","$":"Jenapharm GmbH & Co KG"},"Country":{"@id":"DD","$":"East Germany (GDR)"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"1971-01-01T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}},{"Company":{"@id":"24030","$":"Jenapharm GmbH & Co KG"},"Country":{"@id":"DD","$":"East Germany (GDR)"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1748","$":"Plasmacytoma"},"StatusDate":"1971-01-01T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}},{"Company":{"@id":"16183","$":"Ribosepharm GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"1993-12-31T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}},{"Company":{"@id":"16183","$":"Ribosepharm GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"161","$":"Hodgkins disease"},"StatusDate":"1993-12-31T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}},{"Company":{"@id":"16183","$":"Ribosepharm GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"1993-12-31T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}},{"Company":{"@id":"16183","$":"Ribosepharm GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"1993-12-31T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}},{"Company":{"@id":"16183","$":"Ribosepharm GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"1748","$":"Plasmacytoma"},"StatusDate":"1993-12-31T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"507159"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"CZ","$":"Czech Republic"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2011-08-03T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1446092"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"IS","$":"Iceland"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2011-08-12T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1450906"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"IE","$":"Ireland"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2010-10-08T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1397770"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"NL","$":"Netherlands"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2011-07-01T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1433531"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"ES","$":"Spain"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2010-07-21T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1357151"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"CZ","$":"Czech Republic"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2011-08-03T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1446092"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"IS","$":"Iceland"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2011-08-12T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1450906"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"IE","$":"Ireland"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2010-10-08T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1397770"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"NL","$":"Netherlands"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2011-07-01T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1433531"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"ES","$":"Spain"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2010-07-21T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1357151"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"CZ","$":"Czech Republic"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2011-08-03T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1446092"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"IS","$":"Iceland"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2011-08-12T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1450906"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"IE","$":"Ireland"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2010-10-08T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1397770"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"NL","$":"Netherlands"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2011-07-01T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1433531"}},{"Company":{"@id":"29344","$":"Astellas Pharma GmbH"},"Country":{"@id":"ES","$":"Spain"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2010-07-21T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1357151"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2008-03-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"888407"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2018-12-16T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"2130468"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2008-10-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"958184"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2016-08-26T00:00:00Z","SourceLink":{"@type":"PR","@id":"1791311"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"KR","$":"South Korea"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2011-05-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"1200364"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1745","$":"Follicle center lymphoma"},"StatusDate":"2018-07-02T00:00:00Z","SourceLink":{"@type":"PR","@id":"2050798"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"203","$":"Lymphoma"},"StatusDate":"2019-03-26T00:00:00Z","SourceLink":{"@type":"PR","@id":"2134776"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2010-10-27T00:00:00Z","SourceLink":{"@type":"PR","@id":"1142527"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"KR","$":"South Korea"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2011-05-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"1200364"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2010-10-27T00:00:00Z","SourceLink":{"@type":"PR","@id":"1142527"}},{"Company":{"@id":"17900","$":"H Lundbeck A/S"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2012-08-28T00:00:00Z","SourceLink":{"@type":"PR","@id":"1318503"}},{"Company":{"@id":"17900","$":"H Lundbeck A/S"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2012-08-28T00:00:00Z","SourceLink":{"@type":"PR","@id":"1318503"}},{"Company":{"@id":"1047623","$":"Innopharmax Inc"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2011-09-30T00:00:00Z","SourceLink":{"@type":"PR","@id":"1992824"}},{"Company":{"@id":"1047623","$":"Innopharmax Inc"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2011-09-30T00:00:00Z","SourceLink":{"@type":"PR","@id":"1992824"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"AU","$":"Australia"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2014-06-26T00:00:00Z"},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"AU","$":"Australia"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2014-06-26T00:00:00Z"},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"AU","$":"Australia"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2014-06-26T00:00:00Z"},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2010-07-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"1232992"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"CH","$":"Switzerland"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2009-03-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"1128224"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2010-07-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"1232992"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2010-07-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"1232992"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"HK","$":"Hong Kong"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2009-12-30T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"1083105"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2016-08-26T00:00:00Z","SourceLink":{"@type":"PR","@id":"1791311"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"SG","$":"Singapore"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2010-01-20T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"1083105"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1745","$":"Follicle center lymphoma"},"StatusDate":"2018-07-02T00:00:00Z","SourceLink":{"@type":"PR","@id":"2050798"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"203","$":"Lymphoma"},"StatusDate":"2019-03-26T00:00:00Z","SourceLink":{"@type":"PR","@id":"2134776"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2010-10-27T00:00:00Z","SourceLink":{"@type":"PR","@id":"1142527"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"HK","$":"Hong Kong"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2009-12-30T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"1083105"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2010-10-27T00:00:00Z","SourceLink":{"@type":"PR","@id":"1142527"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"SG","$":"Singapore"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2010-01-20T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"1083105"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2017-03-29T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1904456"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2007-12-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"864020"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2015-12-24T00:00:00Z","SourceLink":{"@type":"PR","@id":"1723613"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"203","$":"Lymphoma"},"StatusDate":"2018-09-27T00:00:00Z","SourceLink":{"@type":"PR","@id":"2077027"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2009-10-30T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"1065038"}},{"Company":{"@id":"17900","$":"H Lundbeck A/S"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2011-09-30T00:00:00Z","SourceLink":{"@type":"PR","@id":"1237808"}},{"Company":{"@id":"17900","$":"H Lundbeck A/S"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2011-09-30T00:00:00Z","SourceLink":{"@type":"PR","@id":"1237808"}},{"Company":{"@id":"1047623","$":"Innopharmax Inc"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2010-02-06T00:00:00Z","SourceLink":{"@type":"PR","@id":"1128224"}},{"Company":{"@id":"1047623","$":"Innopharmax Inc"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2017-03-31T00:00:00Z","SourceLink":{"@type":"PR","@id":"1992824"}},{"Company":{"@id":"1047623","$":"Innopharmax Inc"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2010-02-06T00:00:00Z","SourceLink":{"@type":"PR","@id":"1128224"}},{"Company":{"@id":"1047623","$":"Innopharmax Inc"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2010-02-06T00:00:00Z","SourceLink":{"@type":"PR","@id":"1128224"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2007-11-30T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1233169"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2007-11-30T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1233169"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2007-11-30T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1233169"}},{"Company":{"@id":"29254","$":"Salmedix Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2007-09-21T00:00:00Z"},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2015-12-24T00:00:00Z","SourceLink":{"@type":"PR","@id":"1723613"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"203","$":"Lymphoma"},"StatusDate":"2018-09-27T00:00:00Z","SourceLink":{"@type":"PR","@id":"2077027"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2009-10-30T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"1065038"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2009-10-30T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"1065038"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2005-06-14T00:00:00Z","SourceLink":{"@type":"PR","@id":"607428"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2012-08-06T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1573485"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"17900","$":"H Lundbeck A/S"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"17900","$":"H Lundbeck A/S"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2011-02-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"1166676"}},{"Company":{"@id":"1047623","$":"Innopharmax Inc"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"AU","$":"Australia"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2004-01-31T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1086946"}},{"Company":{"@id":"29254","$":"Salmedix Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2007-01-24T00:00:00Z","SourceLink":{"@type":"PR","@id":"760129"}},{"Company":{"@id":"29254","$":"Salmedix Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2003-09-30T00:00:00Z","SourceLink":{"@type":"PR","@id":"507051"}},{"Company":{"@id":"29254","$":"Salmedix Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2003-09-30T00:00:00Z","SourceLink":{"@type":"PR","@id":"507051"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-05-16T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1907079"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1728","$":"Acute lymphoblastic leukemia"},"StatusDate":"2008-05-31T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1017170"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1731","$":"Acute myelogenous leukemia"},"StatusDate":"2008-05-31T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1017170"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1735","$":"Chronic myelocytic leukemia"},"StatusDate":"2008-05-31T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1017170"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2010-12-31T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1161925"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"3866","$":"Metastatic ovary cancer"},"StatusDate":"2009-04-30T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1439203"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1272","$":"Myelodysplastic syndrome"},"StatusDate":"2008-05-31T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1017170"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"AU","$":"Australia"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2005-06-16T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"607690"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2013-05-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"1416761"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1749","$":"Diffuse large B-cell lymphoma"},"StatusDate":"2010-05-31T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1238746"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2010-07-05T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"1120839"}},{"Company":{"@id":"15872","$":"Eisai Co Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2008-08-18T00:00:00Z","SourceLink":{"@type":"PR","@id":"936155"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"316","$":"B-cell lymphoma"},"StatusDate":"2012-05-10T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1349010"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2013-05-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"1416761"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1749","$":"Diffuse large B-cell lymphoma"},"StatusDate":"2010-05-31T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1238746"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2008-07-16T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"923905"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2010-07-05T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"1120839"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2007-12-24T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"896320"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"KR","$":"South Korea"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2010-03-31T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"1120839"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C1","@sortorder":"10","$":"Phase 1 Clinical"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2010-03-23T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1084933"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C1","@sortorder":"10","$":"Phase 1 Clinical"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2006-11-22T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"783735"}},{"Company":{"@id":"17900","$":"H Lundbeck A/S"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2011-02-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"1166676"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"NZ","$":"New Zealand"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2013-02-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1679139"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"NZ","$":"New Zealand"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-02-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1679139"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"XE","$":"South America"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"1744","$":"Mantle cell lymphoma"},"StatusDate":"2013-02-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1679139"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"XE","$":"South America"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"1069","$":"Metastasis"},"StatusDate":"2013-02-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1679139"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"NZ","$":"New Zealand"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2013-02-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1679139"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"IL","$":"Israel"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"316","$":"B-cell lymphoma"},"StatusDate":"2016-04-20T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1756278"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2007-04-01T00:00:00Z","SourceLink":{"@type":"PR","@id":"842955"}},{"Company":{"@id":"24189","$":"Mundipharma EDO GmbH"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"1828","$":"Multiple myeloma"},"StatusDate":"2007-04-01T00:00:00Z","SourceLink":{"@type":"PR","@id":"842955"}},{"Company":{"@id":"1017747","$":"SymBio Pharmaceuticals Ltd"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"319","$":"Non-Hodgkin lymphoma"},"StatusDate":"2006-08-14T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"686649"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2011-02-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"1166676"}},{"Company":{"@id":"15358","$":"Cephalon Inc"},"Country":{"@id":"XE","$":"South America"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"1734","$":"Chronic lymphocytic leukemia"},"StatusDate":"2011-02-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"1166676"}}]}}}}